EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy

Joseph Schramm iD, Chloe Sholler, Leah Menachery, Laura Vazquez, Giselle Saulnier Sholler

Journal of Clinical Medicine · 07.02.2025 · 14 (4) · 1068

DOI: 10.3390/jcm14041068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.02.2025. Verfasst von Joseph Schramm und 4 weiteren Autor:innen. Beteiligte Einrichtung: Penn State College of Medicine, Penn State University, Hershey, PA 17033, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroblastoma is a common childhood malignancy, and high-risk presentations, including an MYCN amplified status, continue to result in poor survival. Difluoromethylornithine (DFMO) is a new and well-tolerated treatment for high-risk neuroblastoma. This review article discusses preclinical and clinical data that resulted in the establishment of DFMO as a treatment for neuroblastoma. The review of preclinical data includes a summary of the contribution of polyamine synthetic pathways to high-risk neuroblastoma, the effect that MYCN has on polyamine synthetic pathways, and the proposed mechanism by which DFMO inhibits tumorigenesis. This understanding has led to the discussion of various preclinical combination therapies that may result in a synergistic therapeutic response for high-risk neuroblastoma. We review the clinical trials that show the successful treatment of high-risk neuroblastoma with DFMO, including comparative analysis and traditional neuroblastoma trials using propensity score matching. We review the regulatory path by which DFMO gained approval from the Federal Drug Administration for use as a maintenance therapy following the traditional high-risk neuroblastoma therapy. Finally, we discuss the role of DFMO in future clinical research for neuroblastoma and additional pediatric cancers.

Schlagwörter

Stichwörter der Autor:innen

DFMOLIN28neuroblastomareview

Autor:innen und Institutionen

  • Penn State College of Medicine, Penn State University, Hershey, PA 17033, USA.

ORCID-Profile: Joseph Schramm

Zitieren

APA

Schramm, J., Sholler, C., Menachery, L., Vazquez, L., & Saulnier Sholler, G. (2025). Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy. Journal of Clinical Medicine, 14(4), 1068. https://doi.org/10.3390/jcm14041068

Vancouver

Schramm J, Sholler C, Menachery L, Vazquez L, Saulnier Sholler G. Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy. Journal of Clinical Medicine. 2025;14(4):1068. doi:10.3390/jcm14041068

BibTeX
@article{Schramm2025,
  author = {Schramm, Joseph and Sholler, Chloe and Menachery, Leah and Vazquez, Laura and Saulnier Sholler, Giselle},
  title = {Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {1068},
  doi = {10.3390/jcm14041068}
}
Kostenlos starten →